https://www.selleckchem.com/pr....oducts/bgj398-nvp-bg
The HFS was qualified by the European Medicines Agency for antituberculosis drug development in 2015. Here, we describe the standard procedures used to study the growth kinetics of M. tuberculosis in the HFS and the killing effect of first-line antituberculous drugs applied under simulated human PK conditions. This animal-sparing and economical tool can be applied to optimize dosing schedules that minimize emergence of resistance and to prioritize drug regimens that accelerate sterilization.Treatment of tuberculosis necessitat
Like
Comment
Share
